23 publications
| Name | Date | Type | Actions |
|---|---|---|---|
Sales 3rd quarter 2023: 136M€ The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories. |
Public releases | ||
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
Public releases | ||
Universal registration document 2022 Universal Registration Document including the Annual Financial Report |
Reference document | ||
Q1 2023 Sales: €145M Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates. |
Public releases | ||
Document d’enregistrement universel (URD) 2022 version XBRL Document d'enregistrement universel 2022 incluant le rapport financier annuel |
Reference document | ||
Availability of the 2022 universal registration document On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
Public releases | ||
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
Public releases | ||
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) |
Public releases | ||
Vétoquinol announces opening of its first decentralized R&D center in Canada |
Public releases | ||
Vétoquinol to market and distribute Vetprofen in the United States |
Public releases |